arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Sutro Biopharma, Inc.

STRO Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$23.40
Today
as of Jul 22, 16:54 ET
Last 30 days -18.75% Jun 12 → Jul 22
$21.73 $24.85 $27.97 $31.09 $34.21 Jun 12 Jun 22 Jun 29 Jul 08 Jul 15 Jul 22
Open
$28.47
High
$28.67
Low
$25.80
Volume
$294,036
Avg Vol
$143,661
Mkt Cap
$374M
P/E (TTM)
—
Beta
—
52w High
$43.85
52w Low
$6.70
Div Yield
—
Shares Out
$17M

Recent Press Releases & News last 60 days · 1 item

May 28 · 11:24 MT Newswires
Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target

Overview

52-week range
$6.70
$44
45% of range
Avg surprise (last 3)
-2.4%
Avg reaction (last 2)
-3.0%
0% positive
Latest IV / EM
136%
EM ±31.2% · $23 · Aug 21

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.94$-2.24$-1.54$-0.84$-0.14 Actual $-0.64Actual $-0.81Actual $-0.59Actual $-0.59Actual $-0.59Actual $-0.91Est $-0.63Actual $-0.14Est $-0.39Actual $-0.67Actual $-2.94Est $-2.32 JunSepMarJunSepMar/2025Jun/2025SepMar/2026
Revenue vs Net Income Revenue Net income
$-76M$-60M$-44M$-28M$-12M Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu May 14, 2026Mar/2026 $-2.94 $-2.32 -26.7% -223.1% -3.0% earnings
Tue Sep 30, 2025Sep 2025 $-0.67 — — — — financials
Thu Aug 7, 2025Jun/2025 $-0.14 $-0.39 +64.1% — — earnings
Thu May 8, 2025Mar/2025 $-0.91 $-0.63 -44.4% — -3.0% earnings
Mon Sep 30, 2024Sep 2024 $-0.59 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.59 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.59 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.81 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.64 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Aug 6, 2026Jun/2026OTHER -$2.09-$1.40 -49.3%

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-30M—$-48M$-3M$-69M—$-68M$-49M
Net income$-38M—$-57M$-11M$-76M—$-49M$-48M
EPS (diluted)$-2.94—$-0.67$-0.14$-9.08—$-0.59$-0.59

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Cash & equivalents$74M$58M$66M$64M$106M$190M$175M$91M
Inventory————————
Total current assets$221M$151M$182M$232M$287M$343M$406M$443M
Total assets$242M$174M$210M$262M$321M$387M$452M$489M
Long-term debt————————
Total liabilities$309M$306M$297M$294M$347M$343M$341M$337M
Total equity$-67M$-132M$-87M$-32M$-26M$45M$111M$152M

Implied volatility — last 90 days

124%226%329%432%534% Jun 07 — IV 166% · EM ±23.0%Jun 08 — IV 174% · EM ±23.0%Jun 09 — IV 182% · EM ±22.8%Jun 10 — IV 182% · EM ±21.5%Jun 11 — IV 180% · EM ±19.9%Jun 12 — IV 224% · EM ±22.9%Jun 15 — IV 243% · EM ±17.6%Jun 16 — IV 287% · EM ±17.0%Jun 17 — IV 438% · EM ±18.3%Jun 19 — IV 128% · EM ±28.4%Jun 22 — IV 133% · EM ±27.7%Jun 23 — IV 142% · EM ±29.1%Jun 24 — IV 132% · EM ±26.5%Jun 25 — IV 160% · EM ±31.3%Jun 26 — IV 131% · EM ±25.1%Jun 29 — IV 149% · EM ±26.4%Jun 30 — IV 149% · EM ±25.7%Jul 01 — IV 151% · EM ±25.2%Jul 02 — IV 151% · EM ±24.5%Jul 03 — IV 157% · EM ±24.5%Jul 06 — IV 147% · EM ±20.4%Jul 07 — IV 170% · EM ±22.4%Jul 08 — IV 167% · EM ±21.0%Jul 09 — IV 162% · EM ±19.2%Jul 10 — IV 169% · EM ±18.7%Jul 13 — IV 224% · EM ±18.7%Jul 14 — IV 327% · EM ±23.7%Jul 15 — IV 326% · EM ±19.2%Jul 16 — IV 535% · EM ±22.3%Jul 20 — IV 124% · EM ±29.3%Jul 21 — IV 134% · EM ±31.1%Jul 22 — IV 136% · EM ±31.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,162.23-0.1%
JNJ
Johnson & Johnson
$601.7B $255.02-0.2%
ABBV
AbbVie Inc.
$447.7B $256.20+1.1%
MRK
Merck & Company, Inc.
$307.2B $127.47-0.0%
PM
Philip Morris International Inc
$300.4B $195.00+0.3%
NVS
Novartis AG
$293.4B $152.73-0.2%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in